Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repurposed Drugs for Aging, Pain, and Inflammation in Knee Osteoarthritis
2025-524885-12-00Phase 2Withdrawn
- Sponsor
- Radboud University Medical Center
- Start
- May 2026
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of dolutegravir, metformin, colchicine and baricitinib in knee osteoarthritis (OA), sponsored by Radboud University Medical Center. Primary endpoint: Change in epigenetic and biological age acceleration. Planned start May 2026; status: withdrawn.
02
Drugs
dolutegravirmetformincolchicinebaricitinib
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on 2025-524885-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524885-12-00.